Medical device and MedTech insights, news, tips and more

Titan Medical Prices $6m Offering

February 10, 2016

Titan Medical

Titan Medical

 

Titan Medical (CVE:TMD) today priced an 8.9-million-share offering at about 65¢ per share, saying it plans to use the proceeds to continue developing its Sport robot-assisted surgery platform.

Toronto-based Titan said it could gross about $5.8 million (C$8 million) from the offering, which is slated to close Feb 12. Each unit of the offering consists of a share of TMD stock and a warrant to buy another share at about 72¢ (C$1). The stock was trading at C$2.44 apiece today in mid-afternoon activity.

The agent on the deal, Bloom Burton & Co., will take a 7% cash commission on the offering plus 7% of the issued warrants, Titan said. There’s also a 30-day over-allotment option for an additional 15% of the shares that end up being issued, the company said.

Titan Medical’s Sport surgical system is a minimally invasive robotic surgery system featuring the company’s Single Port Orifice Robotic Technology and 3D imaging and interactive instruments, the Toronto, Ontario-based company said.

Last month, Titan Medical introduced the prototype of its Sport robot-assisted surgery device to investors in New York as it gears up for 1st-in-human trials this year.

Titan is chasing TransEnterix (NYSE:TRXC) in the race to challenge robot-assisted surgery’s dominant player, Intuitive Surgical (NSDQ:ISRG), and its da Vinci system. TransEnterix’s SurgiBot is expected to hit the U.S. market during the 1st half of this year; Titan’s Sport offering is anticipated for mid-2017.

Source: Titan Medical prices $6m offering – MassDevice

BY

More insights

June 18, 2026
The Next Frontier in Neurosurgery: What (MedTech) Leaders Need to Know
Learn More
June 11, 2026
10-Person Legacy MEDSearch Named to Forbes America’s Best Executive / Professional Recruiting Firms for the Tenth Time
Learn More
February 26, 2025
The Ripple Effect: How Recent U.S. Tariffs Will Impact Medical Device Sales and Manufacturing in 2025
Learn More

Begin your legacy now. We are your medtech and medical device talent advisory firm.